skip to Main Content

Cro services in

Obesity

At Gubra we have extensive scientific expertise and capabilities to conduct preclinical studies using animal models of obesity. We conduct comprehensive efficacy and mode-of-action studies combining in vivo metabolic profiling with biomarker analysis, histology, whole-brain imaging and RNAseq to evaluate and visualize the effects of your drug candidate.

Why choose Gubra?
  • Expert scientific guidance within obesity
  • Extensive experience in anti-obesity drug profiling
  • Diet-induced obese (DIO) models readily available
  • Tailored study design and rapid initiation
  • Whole-brain 3D imaging of drug responses

Consult with Marco Tozzi

Senior Scientist, Scientific Sales

Advance your obesity drug development with our extensive knowhow.

Choose an experienced partner in anti-obesity drug profiling


Our scientific and technical expertise in the obesity field has enabled us to profile several approved anti-obesity drugs. The combination of Gubra’s extensive knowhow and availability of rodent models guarantees speedy delivery of solid and comprehensive data.

Main Offerings

DIO mice
readily available

Treatment efficacy studies

Real-time food
intake monitoring

Gastric emptying
studies

Taste aversion &
pica behavior

Energy expenditure testing

Accelerate your anti-obesity drug profiling

Models of obesity

Investigate your compound’s mode of action

Acute obesity studies

Cloud-based BRAIN DATA VIEWER

Explore GubraView


GubraView visualizes your compound’s impact and enables fast and effective data mining for your specific brain regions of interest. See your compound’s neurological effects with your own eyes.

Explore

Visualize your compound’s effects

3D Imaging
Video Gallery


Visualize the neurological impacts of your obesity drug candidate. Gubra uses modern whole-brain 3D imaging to provide deeper insight into neurochemical interactions.

Explore

Related pages

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top